Sigilon Therapeutics, Inc is a biotechnology business based in the US. Sigilon Therapeutics shares (SGTX) are listed on the NASDAQ and all prices are listed in US Dollars. Sigilon Therapeutics employs 99 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Sigilon Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – SGTX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Sigilon Therapeutics stock price (NASDAQ: SGTX)Use our graph to track the performance of SGTX stocks over time.
Sigilon Therapeutics shares at a glance
|Latest market close||$11.67|
|52-week range||$5.38 - $54.32|
|50-day moving average||$9.26|
|200-day moving average||$20.45|
|Wall St. target price||$42.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
Buy Sigilon Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Sigilon Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Sigilon Therapeutics price performance over time
|1 week (2021-07-18)||N/A|
|1 month (2021-06-29)||8.96%|
|3 months (2021-04-29)||-20.83%|
|6 months (2021-01-25)||N/A|
|1 year (2020-07-25)||N/A|
|2 years (2019-07-25)||N/A|
|3 years (2018-07-25)||N/A|
|5 years (2016-07-25)||N/A|
Sigilon Therapeutics financials
|Revenue TTM||$12.9 million|
|Gross profit TTM||$-40,114,000|
|Return on assets TTM||-25.21%|
|Return on equity TTM||-85.81%|
|Market capitalisation||$175.6 million|
TTM: trailing 12 months
Shorting Sigilon Therapeutics shares
There are currently 641,029 Sigilon Therapeutics shares held short by investors – that's known as Sigilon Therapeutics's "short interest". This figure is 76.3% up from 363,500 last month.
There are a few different ways that this level of interest in shorting Sigilon Therapeutics shares can be evaluated.
Sigilon Therapeutics's "short interest ratio" (SIR)
Sigilon Therapeutics's "short interest ratio" (SIR) is the quantity of Sigilon Therapeutics shares currently shorted divided by the average quantity of Sigilon Therapeutics shares traded daily (recently around 327055.6122449). Sigilon Therapeutics's SIR currently stands at 1.96. In other words for every 100,000 Sigilon Therapeutics shares traded daily on the market, roughly 1960 shares are currently held short.
To gain some more context, you can compare Sigilon Therapeutics's short interest ratio against those of similar companies.
However Sigilon Therapeutics's short interest can also be evaluated against the total number of Sigilon Therapeutics shares, or, against the total number of tradable Sigilon Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sigilon Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Sigilon Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0453% of the tradable shares (for every 100,000 tradable Sigilon Therapeutics shares, roughly 45 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sigilon Therapeutics.
Find out more about how you can short Sigilon Therapeutics stock.
Sigilon Therapeutics share dividends
We're not expecting Sigilon Therapeutics to pay a dividend over the next 12 months.
Sigilon Therapeutics overview
Sigilon Therapeutics, Inc. , a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017.
Stocks similar to Sigilon Therapeutics
Sigilon Therapeutics in the news
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
new option listings on July 28th
Stocks That Hit 52-Week Lows On Tuesday
Frequently asked questionsWhat percentage of Sigilon Therapeutics is owned by insiders or institutions?
Currently 22.238% of Sigilon Therapeutics shares are held by insiders and 62.788% by institutions. How many people work for Sigilon Therapeutics?
Latest data suggests 99 work at Sigilon Therapeutics. When does the fiscal year end for Sigilon Therapeutics?
Sigilon Therapeutics's fiscal year ends in December. Where is Sigilon Therapeutics based?
Sigilon Therapeutics's address is: 100 Binney Street, Cambridge, MA, United States, 02142
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert